SEC Form 4 · accession 0001179022-15-000081
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin D Freeman
Director
Period of report
Mar 12, 2015
Accepted (ET)
Jul 8, 2015 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 12, 2015 | A | 11,112 | $0.00 | A | 17,112 | D | |
| Common StockF1 | Apr 8, 2015 | A | 10,531 | $0.00 | A | 27,643 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $8.10 | Apr 8, 2015 | D | 14,815 | D | — | Jun 2, 2021 | Common Stock | 14,815 | 0 | D |
Explanation of responses
- F1Amount reported includes shares acquired on June 1, 2015 and previously reported on a Form 4 filed on June 2, 2015. Shares acquired on June 1, 2015 were originally reported as held indirectly by the reporting person, however, such shares are held directly by the reporting person.
- F2The option vested quarterly in eight equal installments beginning September 2, 2011.
- F3The option was canceled by mutual agreement of the reporting person and Galectin Therapeutics, Inc. The reporting person received 10,531 shares of restricted common stock, reported in Table 1 of this Form 4, as consideration for the cancellation of options granted on June 2, 2011 and March 28, 2013.